Form 4: Vigil Neuroscience Director Receives Repriced Stock Options

Samantha L. Budd Haeberlein, a director at Vigil Neuroscience, received repriced stock options as part of the company's 2021 Stock Option and Incentive Plan.

Summary

• On May 3, 2024, Vigil Neuroscience's Board of Directors approved a stock option award repricing for director Samantha L. Budd Haeberlein.
• The repricing is effective as of May 3, 2024, under the terms of the Issuer's 2021 Stock Option and Incentive Plan.
• The exercise price of the repriced stock option award is $3.03 per share, representing the fair market value of the Issuer's Common Stock on the Effective Date.
• A portion of the options, covering 30,694 shares, vests in 36 equal monthly installments starting June 8, 2023.
• Another portion of the options, covering 13,928 shares, vests upon the earlier of June 7, 2024, or the next annual meeting of the Issuer's stockholders.
• If the repriced stock option award is exercised during the Retention Period, it will revert to its original exercise price.
• The Retention Period ends upon the earliest of (i) the one-year anniversary of the Effective Date, (ii) a Sale Event, and (iii) the termination of the Reporting Person's Service Relationship by the Company other than for Cause or due to the Reporting Person's death or disability.

Sentiment

Score: 7

Explanation: The document itself is neutral, simply reporting a transaction. However, the repricing suggests potential past underperformance of the stock, but also a commitment to incentivizing key personnel, leading to a moderately positive sentiment.

Positives

• The repricing of stock options may incentivize the director to improve company performance.
• The new exercise price reflects the current fair market value of the company's stock.

Risks

• The 'Retention Period' could disincentivize the director from exercising the options in the short term.
• If the director's service relationship is terminated for cause, the options may be forfeited.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedules and retention period of the stock options.

Industry Context

Stock option repricing is a common practice to incentivize employees and executives, especially when a company's stock price has declined. This move aims to retain and motivate key personnel by adjusting the option's exercise price to reflect current market conditions.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotechnology industry.
• Repricing of options is not uncommon when a company's stock price underperforms, as it helps to maintain the incentive value of the options.
• Companies like Biogen, Amgen, and Gilead Sciences also utilize stock options as part of their compensation strategy.

Stakeholder Impact

• Shareholders may view the repricing as a positive sign that the company is taking steps to incentivize its leadership.
• Employees may see this as a positive sign of the company's commitment to its leadership team.

Key Dates